Skip to main content

All Articles

Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC

By Charles Bankhead

Immunotherapy, Immunotherapy

May 2018, Vol 8, No 5

Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery

By Corbin Davis

2018 Head and Neck Cancers Symposium, ASTRO Highlights

May 2018, Vol 8, No 5

Blincyto Approved for Patients with B-Cell ALL and Minimal Residual Disease

FDA Approvals, News & Updates

May 2018, Vol 8, No 5

Adcetris Approved as Initial Treatment for Stage III or IV Classical Hodgkin Lymphoma

FDA Approvals, News & Updates

May 2018, Vol 8, No 5

Rubraca Approved as Maintenance Treatment for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

FDA Approvals, News & Updates

May 2018, Vol 8, No 5

Survivorship Guidelines Present Challenges in Primary Care

By Meg Barbor, MPH

May 2018, Vol 8, No 5

Maintaining Work and Productivity a Priority for Cancer Survivors

By Meg Barbor, MPH

May 2018, Vol 8, No 5

Tagrisso Now Approved as First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutations

FDA Approvals, News & Updates

May 2018, Vol 8, No 5

Cabozantinib Active as First-Line Treatment of Differentiated Thyroid Cancer

By Corbin Davis

2018 Head and Neck Cancers Symposium, ASTRO Highlights

May 2018, Vol 8, No 5

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation. Read More ›

Page 212 of 299